Reset
Showing 1 of 1 academic articles

The Downregulation of eIF3a Contributes to Vemurafenib Resistance in Melanoma by Activating ERK via PPP2R1B

Shi-Long Jiang, Shi-Long Jiang, Zhi-Bin Wang, Zhi-Bin Wang et al. • Frontiers in Pharmacology (2021)

Vemurafenib, a BRAF V600E inhibitor, provides therapeutic benefits for patients with melanoma, but the frequent emergence of drug resistance remains a challenge. An understanding of the mechanisms underlying vemurafenib resistance may gener...

DOAJ Open Access (DOAJ) DOI: 10.3389/fphar.2021.720619